8-K: Cerus Reports Strong 2025 Results, Guides 9-11% Revenue Growth

Cerus Corporation announced robust full-year and fourth-quarter 2025 financial results, highlighted by record product revenue and positive non-GAAP adjusted EBITDA for the second consecutive year, alongside 2026 product revenue guidance.

Summary

• Full-year 2025 total revenue reached $233.8 million, marking a 16% increase from 2024.
• Product revenue for full-year 2025 was $206.1 million, up 14% compared to 2024.
• The GAAP net loss attributable to Cerus Corporation narrowed to $15.6 million for full-year 2025, down from $20.9 million in 2024.
• Non-GAAP adjusted EBITDA for full-year 2025 was $9.5 million, an increase from $5.7 million in 2024, marking the second consecutive year of positive adjusted EBITDA.
• The company achieved its highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components in 2025.
• Cash, cash equivalents, and short-term investments stood at $82.9 million as of December 31, 2025.
• Cerus expects full-year 2026 product revenue to be in the range of $224 million to $228 million, representing 9% to 11% year-over-year growth.
• Included in the 2026 guidance, INTERCEPT Fibrinogen Complex (IFC) revenue is projected to be $20 million to $22 million, indicating approximately 20% to 30% year-over-year growth from 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating strong commercial execution, significant revenue growth, and improved profitability metrics, alongside a clear and positive outlook for 2026.

Positives

• Record product revenue of $206.1 million in 2025, representing a 14% increase year-over-year.
• Total revenue increased 16% to $233.8 million in 2025.
• GAAP net loss narrowed to $15.6 million in 2025 from $20.9 million in 2024.
• Achieved positive non-GAAP adjusted EBITDA for the second consecutive year, reaching $9.5 million in 2025, up from $5.7 million in 2024.
• Highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components.
• INTERCEPT Fibrinogen Complex (IFC) demand more than doubled in 2025, with revenue increasing approximately 80% to $16.7 million.
• Entered into a group purchasing agreement with Blood Centers of America (BCA), covering approximately 50% of the U.S. blood supply.
• Generated $4.8 million in operating cash flow for the full year 2025, consistent with expectations for stronger second-half cash generation.
• The INITIATE Phase 4 study, evaluating the routine clinical use of pathogen-inactivated platelets utilizing the INTERCEPT Blood System, commenced in Germany.

Negatives

• Product gross margin decreased to 51.5% in Q4 2025 from 53.9% in Q4 2024, and to 54.5% for full-year 2025 from 55.2% in 2024.
• Higher IFC therapeutic production costs, ongoing trade regulation and inflationary pressures, as well as foreign exchange rates, contributed to the decline in product gross margin percentage.
• Total operating expenses increased 7% in Q4 2025 to $37.2 million and 10.2% for full-year 2025 to $148.6 million.
• Research and development (R&D) expenses increased due to higher government contract costs, workforce-related costs, and increased development costs associated with red blood cell and INT200 programs.
• Full-year 2025 operating cash flow of $4.8 million was lower than the $11.4 million generated in 2024.
• North America platelet kit growth was -3% in Q4 2025, though 4% for the full year.
• Product revenue from the 'Other' region decreased by 32% in Q4 2025 and 27% for the full year 2025.

Risks

• Risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System and IFC.
• The risk that Cerus may not meet its 2026 annual product revenue guidance.
• The risk that Cerus may not effectively continue to launch and commercialize the INTERCEPT Blood System for Cryoprecipitation or INT200.
• Risks that Cerus may not grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contributions from its U.S. and European market agreements.
• Risks related to the uncertain and time-consuming development and regulatory process, including the risk that Cerus may be unable to obtain requisite regulatory approvals to advance its pipeline programs and bring them to market in a timely manner or at all.
• Risks associated with macroeconomic developments, including ongoing military conflict in Ukraine, new or increased tariffs and escalating trade tensions, inflation, rising interest rates, and foreign exchange volatility and the resulting global economic and financial disruptions.
• Risks related to Cerus's ability to demonstrate to the transfusion medicine community and other healthcare constituencies that pathogen reduction and the INTERCEPT Blood System are safe, effective, and economical.
• Risks related to product safety.
• Risks associated with Cerus's ability to maintain an effective, secure manufacturing supply chain, including potential negative impacts from macroeconomic developments, inability of manufacturers to comply with regulatory requirements, and inability to maintain supply agreements with third-party suppliers.
• Risks associated with Cerus's ability to access additional funds under its credit facility and to meet its debt service obligations, and its need for additional funding.
• Risks associated with the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market, and distribute its products.

Future Outlook

Cerus expects full-year 2026 product revenue to be in the range of $224 million to $228 million, representing 9% to 11% year-over-year growth compared to 2025 product revenue. This guidance includes expected full-year 2026 INTERCEPT Fibrinogen Complex (IFC) revenue of $20 million to $22 million, which would represent approximately 20% to 30% year-over-year growth from 2025.

Management Comments

• "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply." William Obi Greenman, President and Chief Executive Officer.
• "This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components." William Obi Greenman.
• "This translated into record product revenue of over $206 million, a narrowing of our GAAP net loss, and positive non-GAAP adjusted EBITDA for the second consecutive year." William Obi Greenman.
• "Looking ahead to 2026, we remain focused on improving global access to our INTERCEPT technologies, advancing our product development programs and building upon the solid financial foundation we have established." William Obi Greenman.

Industry Context

StockSavvy.ai notes that Cerus's continued growth in product revenue and positive adjusted EBITDA, particularly in the pathogen reduction segment, aligns with a broader industry trend towards enhanced blood safety and advanced transfusion medicine technologies. The strategic agreement with Blood Centers of America positions Cerus favorably within the U.S. blood supply chain, a critical market for blood products. The initiation of a Phase 4 study in Germany also highlights ongoing efforts to expand market penetration and clinical validation in key international markets, reflecting the global demand for safer blood components.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against global industry standards.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, narrowing net loss, positive EBITDA, and optimistic 2026 guidance, suggesting improved financial health and future prospects.
• Patients: Enhanced access to INTERCEPT-treated blood components, with an estimated 600,000 patients benefiting in 2025, contributing to safer blood supplies globally.
• Blood Centers/Hospitals: Increased availability and adoption of INTERCEPT technologies, including the new Blood Centers of America agreement, streamlining access to pathogen-reduced blood products.
• Employees: Continued growth and advancement of product development programs suggest stability and potential for further opportunities within the company.

Next Steps

• Host a conference call at 4:30 P.M. ET on March 2, 2026, to discuss financial results and provide a general business overview and outlook.
• Continue improving global access to INTERCEPT technologies.
• Advance product development programs, including the red blood cell and INT200 programs.
• Continue the commercialization and launch of INT200 and IFC.
• Pursue ongoing regulatory review for the INTERCEPT red blood cell system in Europe and late-stage clinical development in the U.S.

Key Dates

Recommendation

The company delivered strong financial performance in 2025 with record product revenue, a narrowed net loss, and positive adjusted EBITDA for the second consecutive year. The 2026 guidance projects continued robust growth, particularly for IFC, and the strategic agreement with Blood Centers of America significantly expands market reach. While gross margins saw a slight dip due to specific cost pressures, the overall trajectory of commercial execution and pipeline advancement suggests a compelling investment opportunity in a critical healthcare sector.

Keywords

Cerus Corporation, CERS, financial results, full-year 2025, Q4 2025, product revenue, INTERCEPT Blood System, pathogen reduction, blood supply, INTERCEPT Fibrinogen Complex, IFC, adjusted EBITDA, medical devices, biotechnology, healthcare, financial guidance, 2026 outlook